Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Aimee Faso

UNC Medical Center
Clinical Pharmacist Practitioner

I am a clinical pharmacist practitioner in oncology at the North Carolina Cancer Hospital in Chapel Hill, NC. I have worked as a pharmacist in oncology since 2004. For over 10 years, I have provided direct care to patients with cancer, including the management of drug-related side effects and disease-related symptoms. I work in a multi-disciplinary environment working with other health care professionals including physicians, advanced practice practitioners, nurses, and clinical research coordinators at an academic medical center. I also serve as an adjunct faculty member at the UNC Eshelman School of Pharmacy and am a Clinical Associate Professor at the UNC School of Nursing. My current area of focus is managing breast cancer patients on oral and IV chemotherapy.